Plexxikon, Wyeth deal

The companies partnered to develop Plexxikon's PLX204 PPAR gamma, alpha and delta agonist to treat Type II diabetes. The deal also includes other Plexxikon small molecules that target PPAR nuclear receptors. Plexxikon said it has completed a "non-IND" safety study of PLX204 in humans. ...